Early molecular diagnosis of BRAF status drives the neurosurgical management in BRAF V600E-mutant pediatric low-grade gliomas: a case report
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2431
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Early molecular diagnosis of BRAF status drives the neurosurgical management in BRAF V600E-mutant pediatric low-grade gliomas: a case report ; volume:22 ; number:1 ; day:29 ; month:11 ; year:2022 ; pages:1-6 ; date:12.2022
BMC pediatrics ; 22, Heft 1 (29.11.2022), 1-6, 12.2022
- Urheber
-
Piccolo, Gianluca
Verrico, Antonio
Morana, Giovanni
Piatelli, Gianluca
Marco, Patrizia De
Iurilli, Valentina
Antonelli, Manila
Gaggero, Gabriele
Ramaglia, Antonia
Crocco, Marco
Caruggi, Samuele
Milanaccio, Claudia
Garrè, Maria Luisa
Pavanello, Marco
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12887-022-03711-6
- URN
-
urn:nbn:de:101:1-2023020921074606033037
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:44 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Piccolo, Gianluca
- Verrico, Antonio
- Morana, Giovanni
- Piatelli, Gianluca
- Marco, Patrizia De
- Iurilli, Valentina
- Antonelli, Manila
- Gaggero, Gabriele
- Ramaglia, Antonia
- Crocco, Marco
- Caruggi, Samuele
- Milanaccio, Claudia
- Garrè, Maria Luisa
- Pavanello, Marco
- SpringerLink (Online service)
Ähnliche Objekte (12)
Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
BRAF non-V600E more frequently co-occurs with IDH1/2 mutations in adult patients with gliomas than in patients harboring BRAF V600E but without a survival advantage
BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature
BCL-XL inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAF V600E colorectal cancer
Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy
Validierung eines Protokolls zur manuellen, mutationsspezifischen BRAF V600E Immunhistochemie
RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAF V600E metastatic colorectal cancer
BRAF V600E mutation mediates FDG-methionine uptake mismatch in polymorphous low-grade neuroepithelial tumor of the young
BRAF and MEK Inhibitor Treatment for Metastatic Undifferentiated Sarcoma of the Spermatic Cord with BRAF V600E Mutation
Loss of Phd2 cooperates with BRAF V600E to drive melanomagenesis
TERT expression is susceptible to BRAF and ETS-factor inhibition in BRAF V600E /TERT promoter double-mutated glioma
BRAF V600E-Mutant Glioblastoma with Extracranial Metastases Responsive to Combined BRAF and MEK Targeted Inhibition: A Case Report
Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
BRAF non-V600E more frequently co-occurs with IDH1/2 mutations in adult patients with gliomas than in patients harboring BRAF V600E but without a survival advantage
BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature
BCL-XL inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAF V600E colorectal cancer
Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy
Validierung eines Protokolls zur manuellen, mutationsspezifischen BRAF V600E Immunhistochemie
RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAF V600E metastatic colorectal cancer
BRAF V600E mutation mediates FDG-methionine uptake mismatch in polymorphous low-grade neuroepithelial tumor of the young
BRAF and MEK Inhibitor Treatment for Metastatic Undifferentiated Sarcoma of the Spermatic Cord with BRAF V600E Mutation
Loss of Phd2 cooperates with BRAF V600E to drive melanomagenesis
TERT expression is susceptible to BRAF and ETS-factor inhibition in BRAF V600E /TERT promoter double-mutated glioma
BRAF V600E-Mutant Glioblastoma with Extracranial Metastases Responsive to Combined BRAF and MEK Targeted Inhibition: A Case Report
Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
BRAF non-V600E more frequently co-occurs with IDH1/2 mutations in adult patients with gliomas than in patients harboring BRAF V600E but without a survival advantage
BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature
BCL-XL inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAF V600E colorectal cancer
Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy
Validierung eines Protokolls zur manuellen, mutationsspezifischen BRAF V600E Immunhistochemie
RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAF V600E metastatic colorectal cancer
BRAF V600E mutation mediates FDG-methionine uptake mismatch in polymorphous low-grade neuroepithelial tumor of the young
BRAF and MEK Inhibitor Treatment for Metastatic Undifferentiated Sarcoma of the Spermatic Cord with BRAF V600E Mutation
Loss of Phd2 cooperates with BRAF V600E to drive melanomagenesis
TERT expression is susceptible to BRAF and ETS-factor inhibition in BRAF V600E /TERT promoter double-mutated glioma